18 May 2013
Keywords: nevirapine, gains, fast-track, approval, usa, hiv, boehringer
Article | 08 July 1996
Boehringer Ingelheim has been granted approval in the USA to market its
non-nucleoside reverse transcriptase inhibitor Viramune (nevirapine) for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 July 1996
17 May 2013
© 2013 thepharmaletter.com